Enfusion Inc. offers software-as-a-service for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.
IPO Year: 2021
Exchange: NYSE
Website: enfusion.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/10/2024 | $11.00 | Overweight | Morgan Stanley |
2/28/2024 | $9.00 → $8.00 | Neutral → Sell | Goldman |
1/30/2024 | $11.00 → $9.00 | Neutral → Underweight | JP Morgan |
11/7/2023 | $9.00 | Neutral | UBS |
4/3/2023 | $11.00 | Neutral | Piper Sandler |
3/15/2023 | $12.00 | Neutral | JP Morgan |
1/4/2023 | $15.00 → $10.00 | Neutral → Underperform | BofA Securities |
1/3/2023 | $13.00 → $12.00 | Equal-Weight → Overweight | Morgan Stanley |
10/3/2022 | $17.00 → $15.00 | Buy → Neutral | BofA Securities |
12/3/2021 | $24.00 → $22.00 | Equal-Weight | Morgan Stanley |
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
4 - Enfusion, Inc. (0001868912) (Issuer)
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its second quarter 2024 financial results as part of its Q2 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 2Q24 Earnings Conference Call Management will host a conference call today, August 6, 2024, at 8:30 AM ET to discuss the results. To pre-register for the live teleconference of the second quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will al
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its second quarter 2024 financial results before the U.S. financial markets open on Tuesday, August 6, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusion's investm
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its first quarter 2024 financial results as part of its 1Q 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 1Q24 Earnings Conference Call Management will host a conference call today, May 9, 2024, at 8:30 am ET to discuss the results. To pre-register for the live teleconference of the first quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will also be
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its first quarter 2024 financial results before the U.S. financial markets open on Thursday, May 9, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusion's investment
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading software-as-a-service (SaaS) platform for investment managers, has posted its fourth quarter and full year 2023 financial results as part of its 4Q 2023 Shareholder Letter which can be viewed here or by navigating to the Financials section of its Investor Relations website which can be found at http://ir.enfusion.com. 4Q23 Earnings Conference Call Management will host a conference call today, March 12, 2024, at 8:30 am ET to discuss the results. To pre-register for the live teleconference of the fourth quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earn
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its fourth quarter and full year 2023 financial results before the U.S. financial markets open on Tuesday, March 12, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfu
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2023 financial results as part of its 3Q 2023 Shareholder Letter which can be viewed here or by navigating to the Financials section of its Investor Relations website which can be found at http://ir.enfusion.com. 3Q23 Earnings Conference Call Management will host a conference call today, November 7, 2023, at 8:30 am ET to discuss the results. To pre-register for the live teleconference of the third quarter earnings call, please use this link. To access this call, dial (888) 330-2502. The conference ID number is 61821.
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2023 financial results before the U.S. financial markets open on Tuesday, November 7, 2023. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 330-2502. The conference ID number is 61821. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusi
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, has posted its second quarter 2023 financial results as part of its 2Q 2023 Shareholder Letter which can be viewed here or by navigating to the Financials section of its Investor Relations website which can be found at http://ir.enfusion.com. 2Q23 Earnings Conference Call Management will host a conference call today, August 8, 2023, at 8:30 am ET to discuss the results. To pre-register for the live teleconference of the second quarter earnings call, please use this link. To access this call, dial (888) 330-2502 (domestic). The conference ID number
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, today announced it will release its second quarter 2023 financial results before the U.S. financial markets open on Tuesday, August 8, 2023. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 330-2502. The conference ID number is 61821. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusio
Morgan Stanley resumed coverage of Enfusion with a rating of Overweight and set a new price target of $11.00
Goldman downgraded Enfusion from Neutral to Sell and set a new price target of $8.00 from $9.00 previously
JP Morgan downgraded Enfusion from Neutral to Underweight and set a new price target of $9.00 from $11.00 previously
UBS initiated coverage of Enfusion with a rating of Neutral and set a new price target of $9.00
Piper Sandler initiated coverage of Enfusion with a rating of Neutral and set a new price target of $11.00
JP Morgan initiated coverage of Enfusion with a rating of Neutral and set a new price target of $12.00
BofA Securities downgraded Enfusion from Neutral to Underperform and set a new price target of $10.00 from $15.00 previously
Morgan Stanley upgraded Enfusion from Equal-Weight to Overweight and set a new price target of $12.00 from $13.00 previously
BofA Securities downgraded Enfusion from Buy to Neutral and set a new price target of $15.00 from $17.00 previously
Morgan Stanley reiterated coverage of Enfusion with a rating of Equal-Weight and set a new price target of $22.00 from $24.00 previously
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its second quarter 2024 financial results as part of its Q2 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 2Q24 Earnings Conference Call Management will host a conference call today, August 6, 2024, at 8:30 AM ET to discuss the results. To pre-register for the live teleconference of the second quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will al
New Portfolio Management Features Elevate Experiences for Asset Managers with Advanced Portfolio Construction, Rebalancing, and Integration with Third-party Optimizers Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the release of the next phase of Portfolio Workbench, bringing even more powerful portfolio rebalancing and construction features to users. Portfolio Workbench enables portfolio managers (PMs) to seamlessly manage and adjust their portfolios using a single intuitive user interface. The newest version adds support for rebalancing across multiple models, integration with portfolio op
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its second quarter 2024 financial results before the U.S. financial markets open on Tuesday, August 6, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusion's investm
As part of the expansion, Richard Earnshaw joins as partner to lead new office and FTV's European investing efforts alongside growing team FTV Capital, a prominent sector-focused growth equity investment firm with a successful 25+-year track record of investing in financial and enterprise technology, today announced the opening of its London office to serve as the firm's hub for UK and European investments. FTV also announced Richard Earnshaw has joined the firm as partner to lead and grow the London-based team while deepening the firm's investing efforts throughout Europe. Located in Mayfair, FTV's London office joins the firm's existing offices in New York, San Francisco and Connecticut
Existing investor FTV Capital to invest additional capital in the Company KKR, a leading global investment firm, today announced that a fund managed by KKR has entered into an agreement to acquire a majority stake in Agiloft ("the Company"), a trusted global leader in data-first contract lifecycle management ("CLM"). As part of the transaction FTV Capital, a sector-focused growth equity firm and an existing investor in Agiloft, will make an additional investment in the Company, and JMI Equity, a growth equity firm focused on investing in leading software companies, will join as a new investor in the Company. The investment will help the Company continue to expand as it grows market share,
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion's Chief Executive Officer, Oleg Movchan, and Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: William Blair's 44th Annual Growth Stock Conference on Wednesday, June 5, 2024 Morgan Stanley US Financials, Payments & CRE Conference on Wednesday, June 12, 2024 Live audio webcasts and archived replays of the events will be available in the Events & Presentations section of the Enfusion Investor Relations website at http://ir.enfusion.com. About Enfus
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its first quarter 2024 financial results as part of its 1Q 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 1Q24 Earnings Conference Call Management will host a conference call today, May 9, 2024, at 8:30 am ET to discuss the results. To pre-register for the live teleconference of the first quarter earnings call, please use this link. To access this call, dial (888) 596-4144. The conference ID number is 9652536. The earnings conference call will also be
Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its first quarter 2024 financial results before the U.S. financial markets open on Thursday, May 9, 2024. Management will host a conference call and webcast that same morning at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To access this call, dial (888) 596-4144. The conference ID number is 9652536. A live webcast of this conference call will be available on the Investor Relations page of Enfusion's website, http://ir.enfusion.com, and a replay will be archived on the website as well. About Enfusion Enfusion's investment
Founder Bob Kaufman transitions to chairman of the board ConnexPay, the world's first all-in-one payments platform, today announced the appointment of Ben Peters as chief executive officer. Peters brings more than two decades of experience leading and scaling global payments and vertical software companies. Bob Kaufman, founder of ConnexPay, will remain actively involved in the business, assuming the role of chairman of the board of directors and working alongside Peters to continue driving ConnexPay's strong growth trajectory. "Under Bob's leadership, ConnexPay has built a unique end-to-end platform to both accept and make payments globally that is transforming payments experiences for
Leading US parking solutions provider, ParkHub, and one of the UK's leading app-based parking platforms, JustPark, agree to merge. Together, ParkHub and JustPark currently serve more than 20 million drivers and over 500 B2B customers, representing $1 billion+ in booking volume. Combination of leading parking technology and payments providers creates robust end-to-end platform to serve entire parking ecosystem in North America and the United Kingdom. This growth acquisition is backed by FTV Capital and existing investor, LLR Partners. ParkHub, a leading North American provider of parking management software and payments solutions, today announced an agreement to combine business
10-Q - Enfusion, Inc. (0001868912) (Filer)
8-K - Enfusion, Inc. (0001868912) (Filer)
8-K - Enfusion, Inc. (0001868912) (Filer)
8-K - Enfusion, Inc. (0001868912) (Filer)
10-Q - Enfusion, Inc. (0001868912) (Filer)
8-K - Enfusion, Inc. (0001868912) (Filer)
ARS - Enfusion, Inc. (0001868912) (Filer)
DEFA14A - Enfusion, Inc. (0001868912) (Filer)
DEF 14A - Enfusion, Inc. (0001868912) (Filer)
8-K - Enfusion, Inc. (0001868912) (Filer)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
SC 13D - Enfusion, Inc. (0001868912) (Subject)
SC 13G/A - Enfusion, Inc. (0001868912) (Subject)
As part of the expansion, Richard Earnshaw joins as partner to lead new office and FTV's European investing efforts alongside growing team FTV Capital, a prominent sector-focused growth equity investment firm with a successful 25+-year track record of investing in financial and enterprise technology, today announced the opening of its London office to serve as the firm's hub for UK and European investments. FTV also announced Richard Earnshaw has joined the firm as partner to lead and grow the London-based team while deepening the firm's investing efforts throughout Europe. Located in Mayfair, FTV's London office joins the firm's existing offices in New York, San Francisco and Connecticut
Founder Bob Kaufman transitions to chairman of the board ConnexPay, the world's first all-in-one payments platform, today announced the appointment of Ben Peters as chief executive officer. Peters brings more than two decades of experience leading and scaling global payments and vertical software companies. Bob Kaufman, founder of ConnexPay, will remain actively involved in the business, assuming the role of chairman of the board of directors and working alongside Peters to continue driving ConnexPay's strong growth trajectory. "Under Bob's leadership, ConnexPay has built a unique end-to-end platform to both accept and make payments globally that is transforming payments experiences for
Forge Global Holdings, Inc. (NYSE:FRGE) ("Forge"), a global private securities marketplace, announced today the appointment of Larry Leibowitz to its Board of Directors, as well as its Compensation Committee. Mr. Leibowitz brings to Forge decades of entrepreneurial and corporate leadership experience in capital markets, financial technology and asset management. He is currently the CEO of Entrypoint Capital, a quantitative investment management firm, and has also held executive and board positions at a myriad of other companies in the financial services and investment sectors, including as the Chief Operating Officer, Head of Global Equities Markets, and Member of the Board of Directors o
Neal Pawar brings decades of experience as a financial services and technology leader to Enfusion, having previously served in executive and leadership roles at AQR Capital Management, D.E. Shaw, Deutsche Bank, and UBS Wealth Management Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, announced today that it has appointed Neal Pawar to serve as Enfusion's Chief Operating Officer (COO) effective November 27, 2023. As Enfusion continues to accelerate its growth trajectory and reinforce its market leadership position, Mr. Pawar will play a key role in shaping the next phase of Enfusion's business str
Seasoned SaaS Marketing Executive to Strengthen RethinkFirst's Leadership in Delivering Data-Driven Behavioral Health Solutions Across the Globe NEW YORK, Sept. 19, 2023 /PRNewswire/ -- RethinkFirst, the leading SaaS software and solutions provider in behavioral health, today announced that it has appointed Lorelei Lenzen Skillman as its new chief marketing officer. Lenzen Skillman brings more than 25 years of experience building and transforming brands through innovative marketing, demand generation and communications programs, and will oversee marketing across all RethinkFirst divisions.
BOSTON and AMSTERDAM and SYDNEY, May 2, 2023 /CNW/ -- Zone & Co, the leading provider of scalable, cloud-based finance operations software solutions built on the Oracle NetSuite platform, today announced the appointment of seasoned FinTech leader Thomas Kim as its new Chief Executive Officer. With this, the company is ready to accelerate its growth and rapidly expand its international footprint. Kim has an extensive background leading innovative financial technology companies through hyper-growth phases. Most recently he served as CEO of Enfusion, a global leader in investment
Veteran public company CFO brings successful FinTech, SaaS, and growth stage company experience Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-native SaaS solutions for investment managers, today announced the appointment of Brad Herring as Chief Financial Officer. "We are pleased to have Mr. Herring join Enfusion's leadership team," said Oleg Movchan, Interim Chief Executive Officer at Enfusion. "He brings a significant and successful track record as a public company CFO along with deep operational, control, compliance, and capital markets experience. We look forward to learning from him as we take Enfusion through the next phase of our growth." Mr. Herring is an a
Deirdre Somers joins as new member of Enfusion's Audit and Nominating and Corporate Governance Committees Enfusion, Inc. (NYSE:ENFN), a leading provider of cloud-native SaaS solutions for investment managers, today announced the appointment of global asset management and financial industry veteran Deirdre Somers to its Board of Directors, effective January 1, 2023. As part of her role, she will sit on the Audit and the Nominating and Corporate Governance Committees. "I am delighted to be joining the Board at Enfusion," said Somers. "It will be a privilege to support a great company delivering great technology at an interesting time in asset management globally." Based in Dublin, Ireland,
Reiterates 2022 Fourth Quarter and Full Year Guidance Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-based investment management software and services, today announced that Stephen Dorton has resigned from his position as Chief Financial Officer, effective January 6, 2023, in order to pursue another career opportunity, and not due to any disagreement with Enfusion's operations, policies or practices. "On behalf of everyone at Enfusion, I would like to thank Steve for his contributions during his tenure as CFO, a time during which the company has undergone breathtaking growth and transformation," said Oleg Movchan, Interim Chief Executive Officer and a member of the B
Reiterates 2022 Third Quarter and Full Year Revenue Guidance Enfusion, Inc. ("Enfusion") (NYSE:ENFN), a leading provider of cloud-based investment management software and services, today announced that its Board of Directors (the "Board") has appointed Oleg Movchan, currently a member of the Board, as Interim Chief Executive Officer, effective August 21, 2022. Mr. Movchan succeeds Thomas Kim, who has resigned as CEO and as a Director of the Company so that he can spend more time with his family. Mr. Movchan has been an Enfusion investor and a Board member for over 10 years, and has worked closely with the Company's management team as Enfusion developed its leading cloud-based investment m
Enfusion (NYSE:ENFN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.04 by 50 percent. This is a 100 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $48.052 million which beat the analyst consensus estimate of $47.616 million by 0.92 percent. This is a 17.28 percent increase over sales of $40.971 million the same period last year.
https://www.sprucepointcap.com/research/enfusion-inc After conducting a forensic review of Enfusion, a technology provider for the investment management industry, Spruce Point believes that financial restatement risk is high and that the company is likely to disappoint investor expectations. Based on our investigation, we estimate a 40% to 60% downside risk.The report highlights several key concerns with the Company, including:Enfusion claims to be a high-growth SaaS provider of financial software with multi-year contracts, but we don't believe it to be a high quality oneThe company has experienced significant executive turnover including the CEO, CFO, Chief Revenue Officer (CRO), and Chief
Gainers Presto Automation (NASDAQ:PRST) shares rose 57.8% to $0.35 during Thursday's pre-market session. The company's market cap stands at $31.9 million. CCSC Technology (NASDAQ:CCTG) shares moved upwards by 31.04% to $4.39. The market value of their outstanding shares is at $50.8 million. Turtle Beach (NASDAQ:HEAR) shares increased by 30.09% to $14.35. The company's market cap stands at $249.7 million. The company's, Q4 earnings came out yesterday. Auddia (NASDAQ:AUUD) stock moved upwards by 22.18% to $3.36. The company's market cap stands at $2.7 million. BigBear.ai Hldgs (NYSE:BBAI) stock rose 19.91% to $2.95. The market value of their outstanding shares is at $647.3 million. Micro
Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Enfusion (NYSE:ENFN) in the last three months. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 0 1 2 1 Last 30D 0 0 0 1 0 1M Ago 0 0 0 0 1 2M Ago 0 0 0 1 0 3M Ago 0 0 1 0 0 In the assessment of 12-month price targets, analysts unveil insights for Enfusion, presenting an average target of $9.0, a high estimate of $10.00, and a low estimate of $8.00. A decline of 2.7% from the prior
B of A Securities analyst Koji Ikeda maintains Enfusion (NYSE:ENFN) with a Underperform and raises the price target from $8 to $9.
Financial outlook 13 These statements are forward-looking and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements. A reconciliation of these forward looking non-GAAP measures to the corresponding GAAP measure is not available without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliations that have not yet occurred, are out of our control, or cannot be reasonably predicted. For the same rea
Enfusion (NYSE:ENFN) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. The company reported quarterly sales of $46.486 million which beat the analyst consensus estimate of $45.275 million by 2.67 percent. This is a 14.73 percent increase over sales of $40.517 million the same period last year.
Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is likely to report earnings for its fourth quarter. • MINISO Group Holding (NYSE:MNSO) is likely to report quarterly earnings at $0.27 per share on revenue of $530.30 million. • BioXcel Therapeutics (NASDAQ:BTAI) is likely to report quarterly loss at $0.91 per share on revenue of $710 thousand. • Enfusion (NYSE:ENFN) is likely to report quarterly earnings at $0.05 per share on revenue of $45.27 million. • Tupperware Brands (NYSE:TUP) is estimated to report earnings for its second quarter. • Kanzhun (NASDAQ:BZ) is expected to report quarterly earnings at $0.16 per share on revenue of $214.08 million. • Manchester United (
Enfusion (NYSE:ENFN) is set to give its latest quarterly earnings report on Tuesday, 2024-03-12. Here's what investors need to know before the announcement. Analysts estimate that Enfusion will report an earnings per share (EPS) of $0.05. Enfusion bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.03, which was followed by a 3.72% increase in the share price